Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients With Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)‐ERIBE
Oncologist - United States
doi 10.1634/theoncologist.2017-0676
Full Text
Open PDFAbstract
Available in full text
Date
November 9, 2018
Authors
Publisher
Alphamed Press